Kiniksa Pharmaceuticals International, plc
- Last sale
- Nov 12, 2026 · +0.46%
- Market cap
- $15.13B
- 157.14M shares
- Filings
- 779
Q3 2026+60.1% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived+436.8% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−9.8% FY25 yoy
- $15.13B
- 138.1×
- 16.0×
- 21.3×
- 1.30%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $677,564,000 | reported | |
| FY 2024 | 2024-12-31 | $423,239,000 | reported | |
| FY 2023 | 2023-12-31 | $270,259,000 | reported | |
| FY 2022 | 2022-12-31 | $220,180,000 | reported | |
| FY 2021 | 2021-12-31 | $38,544,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2018 | $0.00 | — | $0.00 | — | — | — | — |
| FY2017 | $0.00 | — | $0.00 | — | — | — | — |
Segments
Products
LineFY2025ShareChange
Product revenue, net$677.56M100%+62.5%
License and collaboration revenue———
Total$677.56M
Pharmaceutical preparations
Kiniksa Pharmaceuticals International, plc is the 46th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
EBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPCRXPacira BioSciences, Inc.$726.4M3.6%1.0%$1.5BAMPHAmphastar Pharmaceuticals, Inc.$719.9M1.7%13.6%$1.2B
KNSAKiniksa Pharmaceuticals International, plc (this company)$677.6M60.1%8.7%$15.1B
RAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BAXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BTGTXTG Therapeutics, Inc.$616.3M87.3%72.6%$9.8BOPKOpko Health, Inc.$606.9M14.9%37.2%$1.2BINSMInsmed Inc$606.4M66.7%210.5%$25.9BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Kiniksa Pharmaceuticals International, plc · CIK 1730430 · Engraved from SEC EDGAR